Media coverage about Humana (NYSE:HUM) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Humana earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned media headlines about the insurance provider an impact score of 45.5247028004255 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Humana Extends Partnership with Tivity Health to Provide SilverSneakers® Through 2022 (forextv.com)
- Stocks With Rising Relative Strength: Humana (finance.yahoo.com)
- Forbes puts spotlight on Louisville’s aging-care industry (finance.yahoo.com)
- Humana Extends Contract With Tivity Health, Spurs Healthcare (zacks.com)
- Humana’s stock drops after downbeat PDP membership outlook (finance.yahoo.com)
Several analysts have weighed in on the company. Jefferies Group raised Humana from a “hold” rating to a “buy” rating and set a $221.00 target price on the stock in a report on Friday. Goldman Sachs Group assumed coverage on Humana in a report on Wednesday, January 3rd. They issued a “buy” rating and a $305.00 target price on the stock. JPMorgan Chase & Co. lowered Humana from an “overweight” rating to a “neutral” rating and set a $253.00 target price on the stock. in a report on Monday, October 9th. ValuEngine lowered Humana from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, Royal Bank of Canada reissued a “hold” rating and issued a $245.00 target price on shares of Humana in a report on Tuesday, October 10th. Ten equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $258.90.
Humana (NYSE HUM) traded up $2.81 on Friday, hitting $268.02. The company had a trading volume of 1,573,430 shares, compared to its average volume of 1,016,461. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $37,887.92, a price-to-earnings ratio of 21.09, a P/E/G ratio of 1.73 and a beta of 0.88. Humana has a fifty-two week low of $186.25 and a fifty-two week high of $271.99.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, beating analysts’ consensus estimates of $3.27 by $0.12. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $13.41 billion. Humana had a return on equity of 15.99% and a net margin of 3.49%. The business’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter last year, the company earned $3.18 earnings per share. research analysts forecast that Humana will post 11.63 earnings per share for the current fiscal year.
Humana announced that its Board of Directors has initiated a share repurchase program on Thursday, December 14th that allows the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization allows the insurance provider to purchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date of this dividend is Thursday, December 28th. Humana’s payout ratio is currently 12.59%.
In other Humana news, SVP Brian P. Leclaire sold 1,679 shares of the firm’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $245.97, for a total value of $412,983.63. Following the sale, the senior vice president now directly owns 9,888 shares of the company’s stock, valued at approximately $2,432,151.36. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Timothy S. Huval sold 1,382 shares of the firm’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total value of $340,027.28. Following the completion of the sale, the vice president now directly owns 11,557 shares in the company, valued at $2,843,484.28. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,115 shares of company stock worth $2,501,627. 0.80% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Humana (HUM) Earns Daily News Sentiment Score of 0.09” was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/01/13/humana-hum-earns-daily-news-sentiment-score-of-0-09.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.